# Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

> **NCT01064648** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 117 (actual)

## Conditions studied

- Epithelioid Mesothelioma
- Pleural Malignant Mesothelioma
- Recurrent Malignant Mesothelioma
- Sarcomatoid Mesothelioma

## Interventions

- **DRUG:** Cediranib Maleate
- **DRUG:** Cisplatin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Pemetrexed Disodium
- **OTHER:** Placebo Administration

## Key facts

- **NCT ID:** NCT01064648
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-03-15
- **Primary completion:** 2018-06-01
- **Final completion:** 2027-03-31
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01064648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01064648, "Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01064648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*